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ABSTRACT 
Background: A lack of consensus exists among national guidelines regarding who 
should be investigated for haematuria. Type of haematuria and age specific 
thresholds are frequently used to guide referral for investigation of haematuria.  
 
Objectives: To develop and externally validate the haematuria cancer risk score 
(HCRS) to improve patient selection for investigation of haematuria. 
 
Methods: Development cohort comprise of 3,539 prospectively recruited patients 
recruited at 40 UK hospitals (DETECT 1; ClinicalTrials.gov: NCT02676180) and 
validation cohort comprise of 656 Swiss patients. All patients were aged >18 years 
and referred to hospital for the evaluation of visible (VH) and non-visible haematuria 
(NVH). Sensitivity and specificity of the HCRS in the validation cohort was derived 
from a cut-off identified from the discovery cohort.  
 
Results: Patient age, gender, type of haematuria and smoking history were used to 
develop the HCRS. HCRS validation achieves good discrimination (AUC 0.835; 95% 
CI: 0.789-0.880) and calibration (calibration slope=1.215) with no significant 
overfitting (p=0.151). The HCRS detected 11.4% (n=8) more cancers which would 
be missed by UK National Institute for Health and Clinical Excellence guidelines. The 
American Urological Association guidelines would identify all cancers with a 
specificity of 12.6% compared to 30.5% achieved by the HCRS. All patients with 
upper tract cancers would have been identified.  
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Conclusion: The HCRS offers good discriminatory accuracy which is superior to 
existing guidelines. The simplicity of the model would facilitate adoption and improve 
patient and physician decision making.  
 
Key words: bladder cancer; detection; haematuria; nomogram; predict, urinary tract 
cancer 
 
Introduction  
The decision to guide who should have investigations following a presentation of 
haematuria vary between guidelines.[1] Recommendations by the National Institute 
for Health and Care Excellence (NICE) suggest that patients aged ≥45 years with VH 
and ≥60 years with NVH with either dysuria or a raised white cell count on blood test 
should be urgently investigated.[2] Non-urgent referral can be considered for patients 
≥60 years with recurrent or persistent unexplained NVH.[2] In contrast, guidance 
from the American Urology Association (AUA) is that all patients with VH and 
patients with NVH aged ≥35 years should have diagnostic tests although patients 
younger than 35 years may be referred for cystoscopy at the discretion of the 
clinician.[3] 
 
Consistent across guidelines is the use of age specific thresholds to guide referral for 
investigation of VH and NVH as increasing age is an established risk factor for 
bladder cancer. Adopting arbitrary thresholds will invariably result in an increase 
likelihood of missed cancers as well as over investigation of cases unlikely to 
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harbour malignancy. We have previously reported that 3.5% of patients presenting 
with VH and 1.0% of patients with NVH have a diagnosis of malignancy despite not 
meeting the age threshold set out in NICE guidance.[4]  
 
Predictive and prognostic tools using statistical models have been developed in the 
form of nomograms enabling individual patient-specific risk estimation.[5] 
Nomograms often include multiple parameters with the advantage to outperform 
specific individual variables. While numerous prognostic nomograms have been 
developed for bladder cancer, there is only one risk score reported for the prediction 
of a diagnosis of cancer in patients presenting with NVH.[6-8]  
 
In this study, we report the development and external validation of a haematuria 
cancer risk score (HCRS) for the prediction of cancer to enable both patients and 
physicians to easily assess cancer risk following a presentation of haematuria. The 
advantage of a risk assessment approach over the application of arbitrary age 
thresholds allows a more individualized approach with the aim to improve detection 
of cancer and reduce the need for investigations in patients unlikely to have 
malignancy.  
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Material and Methods  
Study design and population 
Both the development and validation cohort comprise patients who were referred to 
secondary care following a presentation of haematuria. NVH was defined as urine 
dipstick of ≥1+ of blood on ≥2 occasions in the discovery cohort.[9] NVH was defined 
by either haematuria on urine dip stick or urine microscopy in the validation cohort 
due to the absence of haematuria guidelines in Switzerland and the variation in 
physician practice patterns. Patients in the development cohort were prospectively 
recruited between March 2016 and June 2017 at 40 UK hospitals while the external 
cohort consist of patients who were retrospectively identified as having haematuria 
investigations between 2011-2017 from the Department of Urology, University of 
Zurich. All patients were ≥18 years and were referred from primary care to 
secondary care following a presentation of haematuria in the community. Study 
design and patient eligibility criteria of the development cohort has been previously 
described.[10]  
 
All patients had no previous history of a bladder cancer diagnosis and evaluation 
comprised of medical history and clinical examination. Patient demographics, 
gender, ethnicity, smoking history and occupation were recorded. Occupational risk 
factor was defined as patients working as gardener, painter, hairdresser/ barber, 
textile worker or metals factory worker.[11] Cystoscopy and upper tract imaging were 
performed for all patients. Where bladder cancer was suspected, patients had a 
transurethral resection of bladder tumour (TURBT) or bladder biopsy under general 
anaesthesia. Bladder cancers were defined as urothelial cell carcinoma and other 
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bladder cancer variants confirmed on histology. Upper tract cancers were also 
confirmed on histology and classified to either upper tract urothelial cancer or renal 
cell cancers.  
 
The development cohort of the study received ethical approval by Health Research 
Authority-North West Liverpool Central Research Ethics Committee on March 2016 
(IRAS project ID: 179245, REC reference: 16/NW/0150). The validation cohort 
received ethical approval by the cantonal ethic committee of Zurich (STV KEK-ZH 
BASEC-Nr. 2016-00158).  
 
Development and validation of a novel haematuria cancer risk score and 
statistical analysis 
Univariate logistic regression was used to determine an association between 
individual variables and bladder cancer. The outcome was bladder cancer which was 
defined as Yes=1 versus No=0. All cases were used for estimating odds ratios. Age 
(years) was analysed as a continuous variable while gender (0=female, 1=male), 
type of haematuria (0=NVH, 1=VH), smoking history (0=non-smoker, 1=ex-smoker, 
2= current smoker, 3=missing) and Ethnicity (0=white, 1=non-white, 2=missing) as 
categorical variables. Multivariate logistic regression model was performed with 
patient’s age, gender, type of haematuria and smoking were used as the final 
predictors for the diagnosis of bladder cancer (0=No vs 1=Yes).  
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A novel HCRS was developed as the linear predictor of the fitted multivariate logistic 
regression in the derivation dataset and fitted as a single predictor to the validation 
dataset. To assess the performance of the HCRS, the area under the curve (AUC) 
was used as a measure of discrimination. The lower and upper 95% confidence 
interval (CI) of the AUC were computed as defined by DeLong et al. [12]. The 
Venkatraman's test for two unpaired receiver operating curves (ROC) was performed 
using 2000 resampling to test the null hypothesis that the true difference in AUC is 
equal to 0.[13] External validation was then performed using the Swiss patient 
cohort. The prediction accuracy of the HCRS was evaluated by the calibration slope 
in the validation dataset. 
 
All statistical analyses were performed with R (R Foundation for Statistical 
Computing; version 3.4.3).[14] All applied tests were two-sided and a p value <0.05 
was accepted as statistically significant. No p-value adjustment was performed for 
multiple comparisons. The development cohort of this study was registered with 
ClinicalTrials.gov:  NCT02676180. 
 
Results  
Patient demographics of the development and validation cohort 
A total of 3,539 and 656 patients were used in the development and validation cohort 
respectively. Descriptive patient characteristics of both study populations are shown 
in Table 1. Univariate logistic regression analysis report that older patients (p<0.001), 
patients with VH (p<0.001), male patients (p<0.001), white patients (p=0.004) and 
patients with a smoking history (p<0.001) were significantly more likely to have a 
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bladder cancer diagnosis. In the development cohort, 285 patients (8.1%) had a 
diagnosis of bladder cancer and 69 patients (10.7%) had a diagnosis of bladder 
cancer in the validation cohort. Occupational risk factor was not associated with the 
diagnosis of bladder cancer (p=0.8). Distribution of patient age stratified by smoking 
history and diagnosis of cancer is described using a box plot in Supplementary 
Figure 1. Bladder cancer histopathological characteristics are shown in 
Supplementary Table 1. 
 
Development of the haematuria cancer risk score  
Spearman’s correlation between bladder cancer predictors showed that no strong 
correlation was observed between predictors (Supplementary Table 2). Multivariate 
logistic regression model report that increasing age (OR 2.9, 95% CI 2.3-3.6, 
p<0.001), VH (OR 3.9, 95% CI 2.6-5.6, p<0.001), male gender (OR 1.8, 95% CI 1.3-
2.4, p<0.001) and smoking history [ex-smoker (OR 1.5, 95% CI 1.1-2.0) & current 
smoker (OR 2.6, 95% CI 1.7-3.8), p<0.001] were independently associated with a 
bladder cancer diagnosis (Table 2). Patients who were ex-smokers were more at risk 
compared to current smokers in univariate logistic regression but following adjusting 
for age in a bivariate logistic regression model and in a multivariate regression 
model, current smokers were more at risk for bladder cancer. The HCRS was 
developed as the linear predictor of the fitted multivariate logistic regression: 
 
Haematuria cancer risk score = 0.055*Age + 1.348*Haematuria type + 0.576*Gender 
+ 0.413*Ex-Smoker + 0.943* Current-Smoker  
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Validation of the haematuria cancer risk score 
Supplementary Figure 2 shows the distribution of the HCRS which were similar 
between the two datasets. Validation the HCRS achieves a good discrimination with 
an AUC=0.768 (95% CI 0.741-0.795) in the development cohort and AUC=0.835 
(95% CI 0.789-0.880) in the validation cohort (Figure 1). No statistically significant 
difference was observed (p=0.1015) between AUC values of the development and 
validation datasets by Venkatraman's test with 2000 bootstraps.[13] The estimated 
calibration slope in the validation dataset was 1.215. The slope is greater than one, 
but it is not significantly different to one (p=0.151) hence, the discrimination seems to 
be preserved. 
 
Table 3 reports the corresponding sensitivity, specificity, true positives and negatives 
and false positives and negatives derived from the ROC curve for selected cut-off 
values. A bootstrap test with 2000 replicates showed no statistically significant 
difference between sensitivities of development and validation cohort 
(Supplementary Table 3). Supplementary Table 4 presents the estimated age cut-off 
for NVH and VH patients by smoking status for female and male patients to identify 
all cancers. Figure 2 illustrates the probability of bladder cancer calculated from the 
fitted multivariate logistic regression model for male and female patients 
incorporating other risk factors such as age, type of haematuria and smoking history. 
Elderly, male smokers with VH had the highest risk of having cancer. Supplementary 
Figure 3 shows the haematuria cancer risk score as a nomogram to guide who 
should be investigated following haematuria. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The development cohort comprised of 55 upper tract cancers (37 renal cell 
carcinoma, 18 upper tract urothelial cancer [UTUC]) while the validation cohort had 
12 upper tract cancers (9 renal cell carcinoma, 3 UTUC). All patients with upper tract 
cancers would have been selected to have haematuria investigations using the 
HCRS of >4.5.   
 
Comparison between haematuria cancer risk score with existing haematuria 
guidelines 
We explored the performance of the HCRS using a defined cut-off of 4.015, where 
patients with a HCRS of ≥4.015 should have investigations following a presentation 
of haematuria. This was based on a sensitivity of approximately 97% for all cancers. 
We then tested the HCRS in the Switzerland patient cohort. In the external validation 
cohort, referral for investigation of haematuria based on NICE guidance would miss 
12.9% (n=9) of all urinary tract cancers (6 bladder cancers, 3 renal cell cancers) 
reporting a sensitivity of 87.1%. Specificity for NICE guidance would equate to 45.7% 
based on 268 true negative cases and 318 false positive cases. The AUA 
recommendation for the investigation of haematuria had a sensitivity of 100% with 80 
true negative cases and 555 false positive cases corresponding to a specificity of 
12.6%.  
 
By comparison, using the same the HCRS threshold (4.015), a sensitivity of 98.6% 
was achieved with a corresponding specificity of 30.5% suggesting that an additional 
11.4% (n=8) of urinary tract cancers were detected which would have been missed if 
NICE guidance were applied. The HCRS missed one bladder cancer, a G3 pT1 
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bladder sarcoma, but reduce the number of patients requiring investigations by 149 
patients.    
 
The AUA guidelines for haematuria would identify all cancers but result in a 
specificity of 3.6% compared to the 30.5% achieved by the risk assessment 
approach. All patients with upper tract cancers would have been referred for 
investigation.  
 
Discussion 
This study represents the development and external validation of a HCRS to 
determine the risk of urinary tract cancer in patients with VH and NVH. We 
constructed the HCRS using patients from a prospective multi-centre observational 
study allowing generalizability throughout the UK. The score was then validated 
using a Swiss patient cohort referred for investigation of haematuria. We show that 
adopting a risk score approach identified significantly more urinary tract cancers 
(11.4%) which would otherwise be missed if NICE guidance was applied and reduce 
the number of patients subjected to investigations compared to AUA guidance.  
 
 
This study has several strengths in its methodology, patient cohort, ease of use and 
practical applicability to real world clinical practice. We used a reasonable sample 
size of 3,539 patients to derive the HCRS. Our model had a good discriminatory 
ability in the validation dataset with an AUC of 0.835 (95% CI 0.789- 0.880) which 
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was higher in comparison to over 60% of prediction risk scores developed by 
Memorial Sloan Kettering Cancer Centre (MSKCC) which have an AUC of 
<0.750.[15]  
 
The prospective multi-centre nature of the development cohort allows for accurate 
data capture by comparison to most risk prediction scores which are derived from 
retrospective studies or population datasets.[7, 8] External validation using a patient 
cohort from a different country confirms the risk score is robust and reproducible 
Finally, variables chosen represent clinical details which are part of the standard 
referral criteria for suspected cancer following a presentation of haematuria. Hence, 
adopting the HCRS would be straight forward without additional time pressures.   
 
Loo and colleagues used electronic medical records (EMR) from Kaiser Permanente 
to identify patients who had investigations for NVH to derive a development cohort of 
1,973 patients and a validation cohort of 657 patients.[16] Patients presenting with 
VH were not accessed. Following multivariable logistic regression, they incorporated 
the following variables in their Haematuria Risk Index: history of VH <6 months, 
patient age ≥50 years, smoking history, male gender, and >25 RBS/HPF on urine 
microscopy with a reported AUC of 0.829. The current study which assesses both 
VH and NVH patients achieves a similar diagnostic performance using fewer 
variables. Limitations include variable quality of data recorded in EMR and both the 
development and validation cohorts were derived from the same EMR.[17] History of 
VH within the last 6 months was used as a variable suggesting that these patients 
were evaluated for VH rather than NVH. Further, some patients did not have 
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complete haematuria investigations and were excluded introducing case selection 
bias. We could not compare our risk score to that of Loo et al. due to difference in 
variables recorded.[16]   
 
Another risk score developed by Wu and colleagues was designed to predict the risk 
of developing bladder cancer based on a case control study of 678 patients.[18] The 
risk score did not have external validation and incorporated clinical variables such as 
smoking history and environmental exposure to carcinogens to achieve an AUC of 
0.70 (95% CI 0.67-0.73). Incorporating mutagen sensitivity data increased the AUC 
to 0.80 (95% 0.72-0.82). The risk score by Wu and colleagues was developed to 
identify patients at risk of developing future bladder cancers who may benefit from 
screening.  
 
Current recommendations from NICE exclude younger patients (<60 years with NVH 
and <45 years with VH) for investigation may result in missed cancers.[4] Age is the 
main discriminating factor across guidelines and we show that the use of the HCRS 
may reduce the risk of missing cancers. In addition to age and type of haematuria, 
smoking history and gender are important risk factors for the development of bladder 
cancer.[1, 19] These variables which are currently not used in the decision to refer 
for investigations but are collected as part of the standard assessment of patients. 
We show that incorporating all four variables in a risk assessment approach would 
improve the patient selection for haematuria investigations compared to current 
recommendations. The fact that 18% of patients diagnosed with bladder cancer 
consult their general practitioner ≥3 times prior to referral for investigations 
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suggesting the need for less restrictive recommendations to enable prompt referral 
for investigations.[20]    
 
There are several limitations in this study. The development cohort reflects a UK 
haematuria referral pattern and although validated in a Swiss population, further 
testing in non-European countries should be considered before use. As discussed 
previously, recent NICE guidance recommend referral for investigations of patients 
with VH aged ≥45 years and ≥60 for patients with NVH. Hence, there may be case 
selection for patients who were investigated although 16.9% of patients investigated 
for haematuria were below these age thresholds. Patients were recruited in 
secondary care and although guidelines for referral exist to aid primary care decision 
making, it is possible that a case selection bias exists whereby not all patients 
presenting with haematuria in primary care are referred for investigations according 
to existing guidelines. The development of a risk assessment tool was not a pre-
planned analysis hence we were limited by the variables we could use. Finally, this 
study does not attempt to address what are the ideal investigations which should be 
used for the investigation of haematuria and we have previously attempted to 
address this in previous studies.[21, 22] 
 
Conclusion 
In this study, we report the development and external validation of a risk assessment 
approach to predict the presence of cancer in patients with VH and NVH. The HCRS 
improves cancer detection rate and performs better than existing criteria to trigger 
referral for haematuria investigations. The simplicity of the model with limited clinical 
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variables would facilitate adoption and improve patient and physician decision 
making.   
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Table 1: Patient demographics of development and validation cohorts.  
 
 
* Age range for discovery cohort: visible haematuria [23-96 years], non-visible 
haematuria [23-90 years] 
** Age range for validation cohort: visible haematuria [18-98 years], non-visible 
haematuria [25-88 years] 
 
 
 
Variables Development cohort (n=3,539) Validation cohort (n=656) 
Age (median, IQR) [range] 68 (57, 76) [23-96]* 
 
57 (47, 68) [18-89]** 
Haematuria, n (%): 
Visible 
Non-visible  
 
2296 (64.9) 
1243 (35.1) 
 
322 (49.1) 
334 (50.9) 
Gender, n (%): 
Male 
Female 
 
2098 (59.3) 
1441 (40.7) 
 
504 (76.8) 
152 (23.2) 
Ethnicity, n (%):  
White  
Non-white 
 
2977 (93.8) 
196 (6.2) 
 
Smoking history, n (%): 
Non-smoker 
Ex-smoker 
Current smoker 
 
1519 (44.6) 
1387 (40.7) 
500 (14.7) 
 
212 (32.3) 
154 (23.5) 
290 (44.2) 
Occupational risk factor, n (%) 
Yes 
No  
 
529 (16.2) 
2743 (83.8) 
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Table 2: Univariate and multivariable logistic regression models associated with bladder cancer in the development cohort. N=3,539 
(Bladder Cancer=285).  
  Univariate  Multivariable 
Predictor Unit IQR-OR† (95% CI) LR χ² (d.f., P) 
 
IQR-OR† (95% CI) Δχ² (d.f., P) 
Age years 2.931 (2.377, 3.614) 120.07 (1, <2.2e-16) 
 
2.892 (2.319, 3.605) 120.07 (1, <2.2e-16) 
Haematuria 
Non-visible 1 (ref) 
  
  
Visible 4.526 (3.127, 6.551) 89.007 (1, <2.2e-16) 
 
3.850 (2.629, 5.638) 84.119 (1, <2.2e-16) 
Smoker* 
Non-smoker 1 (ref) 
  
  
Ex-smoker 1.917 (1.453, 2.531) 
 
1.512 (1.132, 2.018)  
Current 
smoker 1.619 (1.112, 2.357)  
 
2.568 (1.719, 3.836)  
Missing* 1.223 (0.621, 2.410) 22.638 (3, 4.8e-05)  1.283 (0.636, 2.585) 24.257 (3, 2.2e-05) 
Gender 
Female 1 (ref)     
Male 2.960 (2.196, 3.990) 60.044 (1, 9.3e-15)  1.779 (1.298, 2.438) 13.812 (1, 2.0e-04) 
Ethnicity** 
White 1 (ref)     
Non-White 0.490 (0.248, 0.967)    NSS 
Missing* 0.496 (0.274, 0.896) 11.097 (2, 0.00389)    
 
† Interquartile-range odds ratios for continuous predictors and simple odds ratios for categorical predictors. 
 
Model LR χ² (d.f, P) = 242.257 (6, <2.2e-16) 
* Fourth category for Smoking 'missing' was created and compared to non-smokers category in the logistic regression 
analysis 
** Third category for Ethnicity and compared to White category in the logistic regression analysis  
Harrell’s c-index = 0.768 (95%CI: 0.741, 0.795) 
Abbreviations: IQR: Interquartile Range; OR: Odds Ratios; CI: confidence interval; LR: likelihood ratio; χ²: chi-square test (degrees of freedom, p-value); Δχ²: delta chi-square 
(degrees of freedom, p-value), terms added sequentially (first to last). NSS: Not Statistically Significant.   
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Table 3: Hematuria cancer risk score cut offs with corresponding sensitivity, specificity, true positive and negative and false positive 
and negative derived from ROC curve in the development and validation cohort. 
 Development cohort   Validation cohort 
Cut-off TP FN FP TN Specificity (95% CI) Sensitivity (95% CI)  TP FN FP TN Specificity (95% CI) Sensitivity (95% CI) 
3.240 282 3 3058 196 0.060 (0.053, 0.069) 0.993 (0.982, 1.000)  70 0 517 69 0.118 (0.092, 0.143) 1.000 (1.000, 1.000) 
3.897 279 6 2748 506 0.156 (0.143, 0.168) 0.979 (0.961, 0.993)  69 1 428 158 0.270 (0.232, 0.306) 0.986 (0.957, 1.000) 
4.015 277 8 2656 598 0.184 (0.170, 0.198) 0.972 (0.954, 0.989)  69 1 406 180 0.305 (0.268, 0.346) 0.986 (0.957, 1.000) 
4.334 274 11 2380 874 0.269 (0.254, 0.284) 0.961 (0.937, 0.982)  67 3 336 250 0.425 (0.386, 0.468) 0.957 (0.914, 1.000) 
4.386 271 14 2337 917 0.282 (0.267, 0.298) 0.951 (0.923, 0.975)  66 4 324 262 0.445 (0.406, 0.486) 0.943 (0.886, 0.986) 
4.492 268 17 2239 1015 0.312 (0.296, 0.329) 0.940 (0.912, 0.965)  65 5 296 290 0.494 (0.454, 0.536) 0.929 (0.871, 0.986) 
4.559 265 20 2171 1083 0.333 (0.317, 0.349) 0.930 (0.898, 0.958)  65 5 285 301 0.512 (0.473, 0.556) 0.929 (0.871, 0.986) 
4.681 263 22 2050 1204 0.370 (0.354, 0.387) 0.923 (0.891, 0.951)  65 5 261 325 0.555 (0.514, 0.596) 0.929 (0.871, 0.986) 
4.681 262 23 2050 1204 0.370 (0.354, 0.387) 0.919 (0.888, 0.951)  65 5 261 325 0.555 (0.514, 0.596) 0.929 (0.871, 0.986) 
4.916 256 29 1806 1448 0.445 (0.428, 0.462) 0.898 (0.863, 0.930)  60 10 216 370 0.631 (0.592, 0.671) 0.857 (0.771, 0.929) 
 
TP: true positive, FN: false negative, FP: false positive, TN: true negative, 95% CI: 95% confidence interval 
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Figures 
Figure 1: ROC curve of the hematuria cancer risk score. AUC 0.768 (95% CI: 0.741, 
0.795) in the development cohort and AUC 0.835 (95% CI: 0.789, 0.880) in the 
validation cohort. The white square, circle and triangle gives 0.972 (95% CI:  0.954, 
0.989), 0.951 (95% CI: 0.923, 0.975) and 0.898 (95 %CI: 0.863, 0.930) sensitivity in 
the development dataset with cut-off values of 4.015, 4.386 and 4.916 respectively. 
Using the same cut-off values, the black square, circle and triangle shows 0.986 
(95% CI: 0.957, 1.000), 0.943 (95% CI: 0.886, 0.986) and 0.857 (95% CI: 0.771, 
0.929) sensitivity in the validation dataset respectively. 
 
Figure 2: Estimated probability of bladder cancer by age, type of hematuria and 
smoking history for male (A) and female (B). 
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Figure 1: ROC curve of the hematuria cancer risk score. AUC 0.768 (95% CI: 0.741, 
0.795) in the development cohort and AUC 0.835 (95% CI: 0.789, 0.880) in the 
validation cohort. The white square, circle and triangle gives 0.972 (95% CI:  0.954, 
0.989), 0.951 (95% CI: 0.923, 0.975) and 0.898 (95 %CI: 0.863, 0.930) sensitivity in 
the development dataset with cut-off values of 4.015, 4.386 and 4.916 respectively. 
Using the same cut-off values, the black square, circle and triangle shows 0.986 
(95% CI: 0.957, 1.000), 0.943 (95% CI: 0.886, 0.986) and 0.857 (95% CI: 0.771, 
0.929) sensitivity in the validation dataset respectively. 
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Figure 2: Estimated probability of bladder cancer by age, type of hematuria and 
smoking history for male and female patients.  
 
 
 
 
 
